

Regd. Office :-
330, TRIVIA Complex, Natubhai Circle,
Racecourse, Vadodara – 390007, Gujarat, INDIA
Phone : +91 265 2988903 / 2984803
Website : www.chemcrux.com
Email : girishshah@chemcrux.com



To,
Corporate Relations Department
BSE LIMITED,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001

04th August 2023

Dear Sir/Madam,

Subject: Unaudited Standalone Financial Results for the quarter ended 30th June 2023

Ref: BSE Scrip ID: CHEMCRUX BSE Scrip Code: 540395

We would like to inform that the Board of Directors in its meeting held on 04th August 2023 inter alia, considered and approved the Unaudited Standalone Financial Results for the quarter ended 30th June 2023 as recommended by the Audit Committee.

Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we enclose the Unaudited Standalone Financial Results for the quarter ended 30th June 2023.

Kindly take above as compliance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Board Meeting commenced at 01.00 P.M. and concluded at 06:10 P.M.

Thanking you,

For CHEMCRUX ENTERPRISES LIMITED

Dipika Rajpal
Company Secretary & Compliance Officer

CHEMCRUX ENTERPRISES LIMITED

CIN : L01110GJ1996PLC029329

Reg. Office : 330, TRIVIA Complex, Natubhai Circle, Race Course, Vadodara - 390007

Statement Of Unaudited Financial Results For The Quarter Ended 30th June, 2023

(All amount are in INR Lacs, Unless Otherwise Stated)


	Particulars	Quarter Ended			Year Ended
		30-06-2023 Unaudited	31-03-2023 Audited	30-06-2022 Unaudited	31-03-2023 Audited
	Income				
I	Revenue from Operations	2,228.52	2,000.71	2,690.47	9,515.24
II	Other Income	18.45	17.58	24.11	105.21
III	Total Income (I+II)	2,246.97	2,018.29	2,714.58	9,620.45
	IV Expenses				
	- Cost of Materials Consumed	748.85	1,116.00	1,161.35	4,763.42
	- Purchases of Stock-in-Trade	-	-	-	-
	- Changes in Inventories of Finished Goods, Stock-in-Trade and Work-in-Progress	234.46	-366.11	235.00	-464.33
	- Employee Benefit expenses	267.47	175.10	168.10	791.33
	- Finance costs	31.39	46.55	15.34	81.84
	- Depreciation and Amortisation expenses	57.29	57.60	43.87	203.72
	- Other expenses	591.39	564.53	574.12	2,279.68
	Total Expenses (IV)	1,930.85	1,593.67	2,197.78	7,655.66
V	Profit before tax (III-IV)	316.12	424.62	516.80	1,964.79
VI	Tax Expense:				
	a) Current tax				
	- Current tax	77.49	109.04	127.82	476.26
	- Taxes for earlier years	-	-0.15	-	-0.15
	b) Deferred Tax (Credit)/Charge	6.00	23.37	5.92	52.87
	Total tax expense (VI)	83.49	132.26	133.74	528.98
VII	Profit for the quarter (V-VI)	232.63	292.36	383.06	1,435.81
VIII	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	2.95	11.79		11.79
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0.74	2.97		2.97
	B. (i) Items that will be reclassified to profit or loss	32.03	0.86	3.25	31.76
	(ii) Income tax relating to items that will be reclassified to profit or loss	8.06	0.22	0.82	7.99
	Total Comprehensive Income for the quarter (A(i)-(ii) & B (i)- (ii))				
IX	Total Comprehensive Income for the quarter (VII+VIII)	258.81	301.82	385.49	1,468.40
X	Earnings Per Equity Share				
	a) Basic and Diluted	1.57	1.97	2.59	9.70



Notes to Standalone Financial Results :

- The above financial results have been prepared in accordance with Indian Accounting Standards as prescribed under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
- 1 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules as amended from time to time and other relevant provisions of the Act.
 - 2 The above financials results have been reviewed by the Audit Committee and Approved by the Board of Directors in their Meeting held on 04th August, 2023.
 - 3 The Company is primarily engaged in the business of manufacturing and processing of Bulk Drug Intermediates, which in terms of Ind AS 108, on Operating Segment, constitute a single operating segment.
 - 4 The figures of the corresponding previous periods have been regrouped/reclassified wherever considered necessary to confirm to the figures represented in the current period.

For & on behalf of the Board
For Chemcruz Enterprises Limited



Girishkumar Shah
Whole Time Director
DIN : 00469291

Place : Vadodara
Date : 04th August , 2023



r. j. shah & associates

chartered accountants

R. J. Shah FCA
N. R. Dholakia FCA

D-408, Fifth Floor, Avishkar Complex, Old Padra Road, Vadodara - 390015
T: (O) 9825031128 • e-mail: rjshahassociates@yahoo.com

INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

To,
The Board of Directors,
Chemcrux Enterprises Limited,

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Chemcrux Enterprises Limited** ('The Company') for the **quarter ended 30th June 2023**, read together with the Notes thereon ('the Statement'), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement which is the responsibility of the Company's Management and has been approved by the Board of Directors has been prepared in accordance with recognition and measurement principles laid down in IND AS 34 "Interim Financial Reporting" as prescribed u/s. 133 of the Companies Act, 2012 (the "Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these Statement based on our review.

We conducted our review of the Financial Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free from material misstatement. A review is limited primarily to inquiries of Company Personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with applicable Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013, together with the Notes thereon and read with relevant rules and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For R. J. Shah & Associates
Chartered Accountants
Firm Reg. No.: 109752W



R. J. Shah
Partner
M. No. 034139

Place: Vadodara
Date: 4th August, 2023

UDIN: 23034139DGVPR@W5349